Eliana Milazzo, MD
Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1225522980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $718, 6.4 times the $112 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in SC, where the typical reported total is $2,665.
Across 87 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$250
- Amgen$232
- Insulet Corporation$194
- Ultragenyx Pharmaceutical Inc.$167
- AstraZeneca$113
- Shire North American Group Inc$112
- plus $995 from 22 others
What the payments were for
- Food & beverage$2,063100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $250 |
| Amgen | 13 | $232 |
| Insulet Corporation | 8 | $194 |
| Ultragenyx Pharmaceutical Inc. | 2 | $167 |
| AstraZeneca | 1 | $113 |
| Shire North American Group Inc | 2 | $112 |
| Tandem Diabetes Care, Inc. | 6 | $107 |
| Dexcom, Inc. | 5 | $102 |
| Boehringer Ingelheim | 5 | $88 |
| Corcept Therapeutics | 1 | $88 |
| Acella Pharmaceuticals, LLC | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Abbott | 3 | $58 |
| Radius Health, Inc. | 3 | $51 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| BETA Bionics, Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Novo Nordisk | 2 | $34 |
| Medtronic | 2 | $31 |
| Ascensia Diabetes Care US Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Novartis | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| RGH Enterprises LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Pfizer | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| GSK | 1 | $14 |
How this compares
$2,063 in reported general payments places this provider in the 45th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $182,326 |
| OzempicSemaglutide | 104 | $125,438 |
| TrulicityDulaglutide | 88 | $118,458 |
| JardianceEmpagliflozin | 67 | $94,858 |
| ForteoTeriparatide | 17 | $68,919 |
| FarxigaDapagliflozin Propanediol | 52 | $57,336 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $41,436 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $35,518 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $29,148 |
| BaqsimiGlucagon | 60 | $22,337 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,832 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $9,675 |
| Novolog FlexpenInsulin Aspart | 40 | $8,555 |
| JanuviaSitagliptin Phosphate | 11 | $7,936 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $7,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Baqsimi, Humalog | $250 | $397,098292 claims |
| Novo NordiskOzempic | $34 | $125,438104 claims |
| Boehringer IngelheimJardiance | $88 | $94,85867 claims |
| AstraZenecaFarxiga | $113 | $57,33652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Charleston
- Louis HaenelCharleston$377K
- Beatrice HullCharleston$214K
- Jaimin PatelCharleston$37K
- Jyotika FernandesCharleston$12K
- Kathie HermayerCharleston$4K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.